Skip to content Skip to footer

Covid-19 vaccine: Arcturus Therapeutics and Duke-NUS Medical School Partner

Covid vaccine I Amidst the Coronavirus outbreak, the pharmaceutical industry is shaken into action and one of the results is the partnerships of the innovative resourceful companies from all over the world, collaborating for developing a vaccine to counter this pandemic.  In an effort to curb this virus, two significant companies Arcturus Therapeutics and Duke-NUS Medical School also announced their partnership to develop the Coronavirus COVID-19 vaccine. Professor Thomas M. Coffman, Dean of Duke-NUS Medical School says that it will allow the companies together and be strengthened against fighting this disease.

               Duke-NUS is Singapore’s leading partnership of two high profile institutions, Duke University of Singapore and the National University of Singapore NUS and offers a unique curriculum to train the students in unique, multifaceted aspects of medical sciences. The Institutions’ Academic Research-orientation, its resourceful alliances, and innovative developmental nature are credentials that make it a potential leader to develop the COVID-19 vaccine. 

               Arcturus Therapeutics Holdings Inc. (ARCT) is a California based company with resourceful technologies like LUNAR lipid mediated delivery, Unlocked Nucleomonomer Analog (UNA) chemistry, STARR technology for manufacturing multiple nucleic acid (RNA) medicines. Given the specialty in RNA therapeutics, the company has also collaborated with major pharmaceuticals in the past and has a lot of patents in several countries. The company collaborating with DUKE-NUS surely raises the hope and likeability of making a vaccine for the COVID-19 virus.

               The Companies propose an approach using STARR technology combined with LUNAR to make the vaccine for COVID-19. The virus is continuously transmitted between animals and people and can evolve into strains not previously identified in humans which makes this virus a highly adaptive one. The vaccine proposed by the companies will produce proteins inside the human body to tackle the virus. Using nano-particle, non-viral a delivery system that will enable highly functional immune system activity and sustained protein expression in the body. Moreover, the self-replicating RNA-based therapeutic vaccine will trigger rapid and prolonged antigen expression within host cells resulting in protective immunity against infectious pathogens. The technology will also provide rapid screening of different vaccines for effectiveness and safety.

The interesting thing about the technology is that the vaccine produced from it would be highly effective in low dosages which means that once produced, it would be able to reach more people even in its first batch of production. So a massive scale of production would not be needed to vaccinate larger populations of people. It makes this technique to be highly cost-effective and time-efficient for vaccine development. These two qualities are very essential in vaccine development because this virus has spread to a huge portion of the human population globally.

               Despite the efficient technologies used in making this vaccine and companies’ efforts to form candidate in the shortest amount of time possible, the proposed product is still likely to go through clinical trials and approvals from the regulatory authorities before its acceptability usage for the affected people.

Show CommentsClose Comments

Leave a comment